Related Experiment Video
Updated: Jan 18, 2026
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67
Carlos Eduardo Paiva1, Vitor Souza Guimarães2, Alinne Tatiane Faria Silva2
1Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, SP, Brazil; Palliative Care and Quality of Life Research Group (GPQual), Barretos Cancer Hospital, Barretos, SP, Brazil.
Abstract:
In the landscape of breast cancer management, precise assessment of endocrine sensitivity significantly influences therapeutic strategies. The utilization of Ki67, an immunohistochemical marker of tumor proliferation, in tumor rebiopsy holds paramount importance in unraveling breast cancer's response to endocrine therapy. This narrative review aims to elucidate the pivotal role of Ki67 in endocrine sensitivity assessment. We explore the nuanced process of Ki67 evaluation, its timing, and its implications for clinical outcomes in breast cancer patients. From a clinical perspective to pathological response and risk of recurrence, we navigate the spectrum of Ki67's impact. By delving into these facets, we underscore Ki67's potential to guide personalized treatment strategies, shedding light on the intricate interplay between endocrine therapy and clinical outcomes in breast cancer patients.
